

# Bruce C Carleton

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4543046/bruce-c-carleton-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

211  
papers

5,142  
citations

35  
h-index

65  
g-index

232  
ext. papers

6,220  
ext. citations

4.8  
avg, IF

5.42  
L-index

#	Paper	IF	Citations
211	Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C.. <i>Liver International</i> , <b>2022</b> ,	7.9	1
210	A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant women.. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 148, 112684	7.5	0
209	Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury.. <i>Kidney360</i> , <b>2022</b> , 3, 37-50	1.8	0
208	Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study. <i>BMJ Paediatrics Open</i> , <b>2022</b> , 6, e001428	2.4	
207	Identification of Drug Transporter Genomic Variants and Inhibitors that Protect Against Doxorubicin-Induced Cardiotoxicity. <i>Circulation</i> , <b>2021</b> ,	16.7	5
206	Hydroxyzine Use in Preschool Children and Its Effect on Neurodevelopment: A Population-Based Longitudinal Study.. <i>Frontiers in Psychiatry</i> , <b>2021</b> , 12, 721875	5	
205	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	1
204	A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol. <i>Canadian Journal of Kidney Health and Disease</i> , <b>2021</b> , 8, 20543581211057708	2.3	0
203	127 Impact of CYP2D6, CYP3A4, and CYP2C9 pharmacogenomic profile on pain relief and adverse events in Canadian children treated with oxycodone and ibuprofen. <i>Paediatrics and Child Health</i> , <b>2021</b> , 26, e90-e90	0.7	
202	DRESS induced by amoxicillin-clavulanate in two pediatric patients confirmed by lymphocyte toxicity assay. <i>Allergy, Asthma and Clinical Immunology</i> , <b>2021</b> , 17, 37	3.2	0
201	Pharmacoepidemiology: A time for a new multidisciplinary approach to precision medicine. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> , 30, 985-992	2.6	
200	Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study. <i>The Lancet Child and Adolescent Health</i> , <b>2021</b> , 5, 274-283	14.5	13
199	Integrating disease and drug-related phenotypes for improved identification of pharmacogenomic variants. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 251-261	2.6	1
198	Pharmacogenetic testing to guide therapeutic decision-making and improve outcomes for children undergoing anthracycline-based chemotherapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> ,	3.1	2
197	Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 161, 103312	7	4
196	Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicity. <i>Npj Genomic Medicine</i> , <b>2021</b> , 6, 35	6.2	0
195	COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2021</b> , 99, 577-588	2.4	

194	Vaccinomics: a cross-sectional survey of public values. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 17, 2999-3015	4.4	0
193	TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 64	9.8	1
192	Guillain-Barré Syndrome Following Influenza Vaccines Affords Opportunity to Improve Vaccine Confidence. <i>Journal of Infectious Diseases</i> , <b>2021</b> , 223, 355-358	7	3
191	Challenges and Opportunities in Implementing Pharmacogenetic Testing in Clinical Settings. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2021</b> , 61, 65-84	17.9	7
190	Pharmacogenomics in Pediatric Oncology: Mitigating Adverse Drug Reactions While Preserving Efficacy. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2021</b> , 61, 679-699	17.9	3
189	Deliberations about clinical pharmacogenetic testing in pediatric oncology. <i>Personalized Medicine</i> , <b>2021</b> , 18, 399-405	2.2	1
188	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1550-1558	13.4	4
187	The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments. <i>Cancer</i> , <b>2021</b> ,	6.4	5
186	An observational cohort study comparing ibuprofen and oxycodone in children with fractures. <i>PLoS ONE</i> , <b>2021</b> , 16, e0257021	3.7	3
185	RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. <i>Cell Stem Cell</i> , <b>2021</b> , 28, 2076-2089.e7	18	4
184	Novel variant in glycoprotein c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 143, 112195	7.5	0
183	Epidemiologic Characteristics of Acute Kidney Injury During Cisplatin Infusions in Children Treated for Cancer. <i>JAMA Network Open</i> , <b>2020</b> , 3, e203639	10.4	10
182	An update on CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 723-734	5.5	4
181	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , <b>2020</b> , 98, 2-12	4.3	18
180	Real-World Evidence to Assess Medication Safety or Effectiveness in Children: Systematic Review. <i>Drugs - Real World Outcomes</i> , <b>2020</b> , 7, 97-107	2.2	5
179	Big Data in the Assessment of Pediatric Medication Safety. <i>Pediatrics</i> , <b>2020</b> , 145,	7.4	3
178	Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. <i>Pharmacogenomics Journal</i> , <b>2020</b> , 20, 621-628	3.5	5
177	Pharmacogenomic testing: Enhancing personalized medication use for patients. <i>Canadian Family Physician</i> , <b>2020</b> , 66, 241-243	0.9	1

176	CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. <i>Pharmacogenomics Journal</i> , <b>2020</b> , 20, 306-319	3.5	8
175	Vincristine-induced peripheral neurotoxicity: A prospective cohort. <i>Pediatric Hematology and Oncology</i> , <b>2020</b> , 37, 15-28	1.7	7
174	Pharmacokinetic-Pharmacogenomic Model for Chinese Children Treated With Lamotrigine Also Applies for Mexican Children. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 801-802	3.2	
173	Prevention of adverse drug effects: a pharmacogenomic approach. <i>Current Opinion in Pediatrics</i> , <b>2020</b> , 32, 646-653	3.2	1
172	Pseudotumor cerebri syndrome with different types of hormonal contraceptives in women of child-bearing age. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 2625-2629	6	3
171	Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1444-1450	15.1	12
170	Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2019</b> , 25, 697-704	1.9	3
169	Drs. He et al. Reply to Drs. Lai and Brown. <i>Pharmacotherapy</i> , <b>2019</b> , 39, 792-793	5.8	
168	Outcome Definition Influences the Relationship Between Genetic Polymorphisms of , , and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. <i>Genes</i> , <b>2019</b> , 10,	4.2	10
167	Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 350-359	6.1	9
166	Risk of Gynecomastia with Users of Proton Pump Inhibitors. <i>Pharmacotherapy</i> , <b>2019</b> , 39, 614-618	5.8	6
165	Morphine biotransformation genes and neonatal clinical factors predicted behaviour problems in very preterm children at 18 months. <i>EBioMedicine</i> , <b>2019</b> , 40, 655-662	8.8	16
164	A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. <i>PLoS ONE</i> , <b>2019</b> , 14, e0210646	3.7	11
163	Oral Fluoroquinolone Prescribing to Children in the United States From 2006 to 2015. <i>Pediatric Infectious Disease Journal</i> , <b>2019</b> , 38, 268-270	3.4	3
162	Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 402-410	6.1	36
161	Genome-Wide Association Studies of Drug-Induced Liver Injury Make Progress Beyond the HLA Region. <i>Gastroenterology</i> , <b>2019</b> , 157, 1167-1168	13.3	
160	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. <i>JMIR Research Protocols</i> , <b>2019</b> , 8, e11868	2	8
159	Comparison of Valvulopathy Risk with Lorcaserin and Phenterminetopiramate for Weight Loss. <i>Current Drug Therapy</i> , <b>2019</b> , 14, 74-78	0.7	

158	Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2019</b> , 39, 675-676	1.7	0
157	Association of Gabapentin or Pregabalin Use and Incidence of Acute Angle-closure Glaucoma. <i>Journal of Glaucoma</i> , <b>2019</b> , 28, 777-779	2.1	1
156	Oral fluoroquinolones and risk of fibromyalgia. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 236-239.8	3.8	5
155	CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 173, 521-532	4.4	18
154	The incidence of symptomatic osteonecrosis after allogeneic haematopoietic stem cell transplantation in children with acute lymphoblastic leukaemia - controversy on dexamethasone as a risk factor. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 958-959	4.5	1
153	Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety Database. <i>Journal of Clinical Pharmacology</i> , <b>2019</b> , 59, 356-369	3.9	6
152	Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. <i>Lancet Oncology</i> , <b>2019</b> , 20, e29-e41	21.7	46
151	Considerations for Implementing Precision Therapeutics for Children. <i>Clinical and Translational Science</i> , <b>2019</b> , 12, 140-150	4.9	8
150	Tumor necrosis factor inhibitors and risk of peripheral neuropathy in patients with rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 1083-1086	5.3	6
149	Association of Postoperative Topical Prostaglandin Analog or Beta-Blocker Use and Incidence of Pseudophakic Cystoid Macular Edema. <i>Journal of Glaucoma</i> , <b>2018</b> , 27, 402-406	2.1	21
148	Assessment of hair cortisol as a potential biomarker for possible adrenal suppression due to inhaled corticosteroid use in children with asthma: A retrospective observational study. <i>Clinical Biochemistry</i> , <b>2018</b> , 56, 26-32	3.5	5
147	Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 574-581	6.1	139
146	Further Investigation of the Role of and Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1866-1871	12.9	20
145	An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines. <i>Pediatric Blood and Cancer</i> , <b>2018</b> , 65, e26887	3	3
144	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2018</b> , 6, 38-69	5.4	89
143	Genetic variation in predicts phenytoin-induced maculopapular exanthema in European-descent patients. <i>Neurology</i> , <b>2018</b> , 90, e332-e341	6.5	33
142	Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy. <i>PM and R</i> , <b>2018</b> , 10, 235-243	2.2	16
141	Statin medications and the risk of gynecomastia. <i>Clinical Endocrinology</i> , <b>2018</b> , 89, 470-473	3.4	6

140	Common variation near IRF6 is associated with IFN- $\gamma$ -induced liver injury in multiple sclerosis. <i>Nature Genetics</i> , <b>2018</b> , 50, 1081-1085	36.3	28
139	Risk of Anterior Segment Complications Associated With the Live Herpes Zoster Vaccine: Evidence From a Health-Claim Database. <i>Cornea</i> , <b>2018</b> , 37, 952-956	3.1	5
138	Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review. <i>CNS Drugs</i> , <b>2018</b> , 32, 917-938	6.7	13
137	Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines - Multi-country assessment. <i>Vaccine</i> , <b>2018</b> , 36, 6202-6211	4.1	26
136	Activated protein C as disease-modifying therapy in antenatal preeclampsia: An open-label, single arm safety and efficacy trial. <i>Pregnancy Hypertension</i> , <b>2018</b> , 13, 121-126	2.6	3
135	Association of Antidepressant Use With Drug-Related Extrapyrmidal Symptoms: A Pharmacoepidemiological Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2018</b> , 38, 349-356	1.7	16
134	HUME: large-scale detection of causal genetic factors of adverse drug reactions. <i>Bioinformatics</i> , <b>2018</b> , 34, 4274-4283	7.2	5
133	Analyses of Adverse Drug Reactions Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety (CPNDS) database. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, OR11-3	0	
132	Risk of hair loss with different antidepressants: a comparative retrospective cohort study. <i>International Clinical Psychopharmacology</i> , <b>2018</b> , 33, 44-48	2.2	1
131	Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0204799	3.7	10
130	Risk of Pseudotumor Cerebri Syndrome (PTCS) with hormonal contraceptive use. <i>International Journal of Reproduction, Contraception, Obstetrics and Gynecology</i> , <b>2018</b> , 7, 778	0.1	1
129	In Reply: Controversies on the Use of Glaucoma Medications During Surgery. <i>Journal of Glaucoma</i> , <b>2018</b> , 27, e195-e196	2.1	2
128	Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review. <i>Frontiers in Pharmacology</i> , <b>2018</b> , 9, 1111	5.6	24
127	The influence of genetic variation on late toxicities in childhood cancer survivors: A review. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 126, 154-167	7	22
126	Response to. <i>Paediatrics and Child Health</i> , <b>2018</b> , 23, 239	0.7	
125	Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , <b>2017</b> , 4, 2054358117690338	2.3	11
124	Asthma in British Columbia: Are we finally breathing easier? A population-based study of the burden of disease over 14 years. <i>Journal of Asthma</i> , <b>2017</b> , 54, 308-317	1.9	4
123	Fluoroquinolone Use and Risk of Carpal Tunnel Syndrome: A Pharmacoepidemiologic Study. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 684-686	11.6	6

122	Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1558-1562	13.4	29
121	Improved strength on 5-hydroxytryptophan and carbidopa in spinal cord atrophy. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 378, 59-62	3.2	5
120	Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. <i>Journal of Clinical Psychopharmacology</i> , <b>2017</b> , 37, 102-104	1.7	35
119	Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. <i>BMJ Open</i> , <b>2017</b> , 7, e016276	3	2
118	Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 1143-1145	3.8	9
117	Association of Repeated Intravitreal Bevacizumab Injections With Risk for Glaucoma Surgery. <i>JAMA Ophthalmology</i> , <b>2017</b> , 135, 363-368	3.9	30
116	Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines. <i>PLoS ONE</i> , <b>2017</b> , 12, e0175711	3.7	11
115	Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: Nested case-control study. <i>Neurology</i> , <b>2017</b> , 89, 792-795	6.5	21
114	Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 931-943	2.6	22
113	What Is the Future of Pharmacovigilance and How Can We Make It as Good as Possible? <b>2017</b> , 21-30		1
112	Oral morphine dosing predictions based on single dose in healthy children undergoing surgery. <i>Paediatric Anaesthesia</i> , <b>2017</b> , 27, 28-36	1.8	18
111	Risk of sensorineural hearing loss with macrolide antibiotics: A nested case-control study. <i>Laryngoscope</i> , <b>2017</b> , 127, 229-232	3.6	12
110	Physician and parent barriers to the use of oral corticosteroids for the prevention of paediatric URTI-induced acute asthma exacerbations at home. <i>Paediatrics and Child Health</i> , <b>2017</b> , 22, 190-194	0.7	3
109	Hair cortisol as a hypothalamic-pituitary-adrenal axis biomarker in pregnant women with asthma: a retrospective observational study. <i>BMC Pregnancy and Childbirth</i> , <b>2016</b> , 16, 176	3.2	13
108	Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 423-31	3.2	31
107	Risk of Myocardial Infarction and Stroke With Single or Repeated Doses of Intravitreal Bevacizumab in Age-Related Macular Degeneration. <i>American Journal of Ophthalmology</i> , <b>2016</b> , 163, 53-58	4.9	17
106	The Risk of Narcolepsy Following Receipt of Adjuvanted Pandemic 2009 The Subtype of Influenza A Virus (H1N1) Vaccines: Results of the SOMNIA Global Collaborative Study. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3,	1	2
105	Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics. <i>Pharmacogenetics and Genomics</i> , <b>2016</b> , 26, 28-39	1.9	14

104	Risk of Extrapyrimal Adverse Events With Aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , <b>2016</b> , 36, 472-4	1.7	9
103	An in silico framework for integrating epidemiologic and genetic evidence with health care applications: ventilation-related pneumothorax as a case illustration. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2016</b> , 23, 711-20	8.6	4
102	Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. <i>Paediatric Drugs</i> , <b>2016</b> , 18, 251-60	4.2	23
101	Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. <i>British Journal of Clinical Pharmacology</i> , <b>2016</b> , 82, 683-95	3.8	129
100	Hair cortisol as a novel biomarker of HPA suppression by inhaled corticosteroids in children. <i>Pediatric Research</i> , <b>2015</b> , 78, 44-7	3.2	19
99	Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 1065-76	2.6	73
98	A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. <i>Nature Genetics</i> , <b>2015</b> , 47, 1079-84	36.3	155
97	Use of pharmacogenomics in pediatric renal transplant recipients. <i>Frontiers in Genetics</i> , <b>2015</b> , 6, 41	4.5	7
96	Pathways to Overmedication and Polypharmacy: Case Examples from Adolescents with Fetal Alcohol Spectrum Disorders <b>2015</b> , 125-148		8
95	Association between regulatory advisories and codeine prescribing to postpartum women. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1861-2	27.4	10
94	A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose. <i>Clinical Pharmacokinetics</i> , <b>2015</b> , 54, 1083-90	6.2	12
93	Post-renal transplant erythrocytosis: a case report. <i>Pediatric Transplantation</i> , <b>2015</b> , 19, E7-10	1.8	2
92	Genetic determinants of cocaine-associated agranulocytosis. <i>BMC Research Notes</i> , <b>2015</b> , 8, 240	2.3	11
91	Risperidone and Risk of Gynecomastia in Young Men. <i>Journal of Child and Adolescent Psychopharmacology</i> , <b>2015</b> , 25, 671-3	2.9	10
90	Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1413	1.8	16
89	ISDN2014_0424: Challenging/disruptive sleep/wake behaviours in adolescents with fetal alcohol spectrum disorders: Iatrogenic effects of prescription medications. <i>International Journal of Developmental Neuroscience</i> , <b>2015</b> , 47, 128-128	2.7	
88	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 428-36	3.2	44
87	New Ways of Detecting ADRs in Neonates and Children. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 5643-93.3		2



86	Codeine-related deaths: The role of pharmacogenetics and drug interactions. <i>Forensic Science International</i> , <b>2014</b> , 239, 50-6	2.6	33
85	Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. <i>Epilepsia</i> , <b>2014</b> , 55, 496-506	6.4	142
84	Pharmacogenomic diversity in Singaporean populations and Europeans. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 555-63	3.5	14
83	Hearing loss in Mexican children treated with cisplatin. <i>International Journal of Pediatric Otorhinolaryngology</i> , <b>2014</b> , 78, 1456-60	1.7	14
82	Exome sequencing pilot study in children with carbamazepine-induced serious skin reactions. <i>Clinical and Translational Allergy</i> , <b>2014</b> , 4, P119	5.2	78
81	Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity". <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 96, 158	6.1	2
80	Genetic markers of cisplatin-induced hearing loss in children. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 96, 296-8	6.1	7
79	VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. <i>Pediatric Blood and Cancer</i> , <b>2014</b> , 61, 1055-62	3	31
78	Emergency department visits for children with acute asthma: discharge instructions, parental plans, and follow-through of care--a prospective study. <i>Canadian Journal of Emergency Medicine</i> , <b>2014</b> , 16, 467-76	9.6	4
77	Risperidone use and risk for gynecomastia in men. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 656-7	17	2
76	Pharmacogenomics and adverse drug reactions in children. <i>Frontiers in Genetics</i> , <b>2014</b> , 5, 78	4.5	16
75	Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. <i>Expert Opinion on Drug Safety</i> , <b>2014</b> , 13, 1305-17	4.1	7
74	Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 160-70	3.5	23
73	Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 95, 253	6.1	18
72	The emerging era of pharmacogenomics: current successes, future potential, and challenges. <i>Clinical Genetics</i> , <b>2014</b> , 86, 21-8	4	54
71	Development of a broad-based ADME panel for use in pharmacogenomic studies. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1185-95	2.6	8
70	Prescription drug dispensing profiles for one million children: a population-based analysis. <i>European Journal of Clinical Pharmacology</i> , <b>2013</b> , 69, 581-8	2.8	30
69	Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 243-51	6.1	87

68	HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 94, 142-9	6.1	91
67	The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2013</b> , 2, 183-92	4	7
66	High use of health services in patients with suboptimal asthma drug regimens: a population-based assessment in British Columbia, Canada. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 744-51	2.6	13
65	Cancer pharmacogenomics in children: research initiatives and progress to date. <i>Paediatric Drugs</i> , <b>2013</b> , 15, 71-81	4.2	5
64	Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. <i>Multiple Sclerosis and Related Disorders</i> , <b>2013</b> , 2, 57-9	4	8
63	Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 466-72	3.2	14
62	Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. <i>Pediatric Blood and Cancer</i> , <b>2013</b> , 60, 1375-81	3	117
61	Life-threatening adverse events following therapeutic opioid administration in adults: is pharmacogenetic analysis useful?. <i>Pain Research and Management</i> , <b>2013</b> , 18, 133-6	2.6	12
60	Physician variability in treating pain and irritability of unknown origin in children with severe neurological impairment. <i>Pain Research and Management</i> , <b>2013</b> , 18, 243-8	2.6	18
59	A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. <i>PLoS ONE</i> , <b>2013</b> , 8, e70073	3.7	27
58	Pharmacogenomics of vincristine-induced neurotoxicity in pediatric cancer patients. <i>FASEB Journal</i> , <b>2013</b> , 27, 666.3	0.9	
57	Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , <b>2013</b> , 20, e110-27	3.3	2
56	Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , <b>2013</b> , 20, e369-96	3.3	16
55	Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. <i>Journal of Pediatrics</i> , <b>2012</b> , 160, 33-7.e2	3.6	81
54	More codeine fatalities after tonsillectomy in North American children. <i>Pediatrics</i> , <b>2012</b> , 129, e1343-7	7.4	289
53	Apnea and Oxygen Desaturations in Children Treated with Opioids after Adenotonsillectomy for Obstructive Sleep Apnea Syndrome. <i>Paediatric Drugs</i> , <b>2012</b> , 14, 411-415	4.2	24
52	Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. <i>Pharmacogenomics Journal</i> , <b>2012</b> , 12, 233-7	3.5	142
51	Fifty years of pediatric asthma in developed countries: how reliable are the basic data sources?. <i>Pediatric Pulmonology</i> , <b>2012</b> , 47, 211-9	3.5	14

50	Suspected opioid overdose case resolved by CYP2D6 genotyping. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 121-3	3.2	8
49	Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: the devil is in the details. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 378-80	3.2	9
48	Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1422-8	2.2	267
47	Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 91, 692-9	6.1	52
46	Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome: a prospective pilot study. <i>Paediatric Drugs</i> , <b>2012</b> , 14, 411-5	4.2	7
45	Using pharmacogenetics to understand adverse drug reactions in children. <i>Paediatrics and Child Health</i> , <b>2011</b> , 16, 537-8	0.7	5
44	CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 425-32	3.2	35
43	Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. <i>Journal of Cardiovascular Pharmacology</i> , <b>2011</b> , 58, 228-39	3.1	16
42	Response to Pharmacogenetics: Call to Action. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 90, 507-508.	6.1	1
41	Sildenafil citrate therapy for severe early-onset intrauterine growth restriction. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>2011</b> , 118, 624-8	3.7	133
40	Pharmacogenetic testing: time for clinical practice guidelines. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 924-7	6.1	41
39	The use of conferencing technologies to support drug policy group knowledge exchange processes: an action case approach. <i>International Journal of Medical Informatics</i> , <b>2011</b> , 80, 251-61	5.3	6
38	A literature review on distance knowledge exchange in healthcare groups: what can we learn from the ICT literature?. <i>Journal of Medical Systems</i> , <b>2011</b> , 35, 639-46	5.1	3
37	Technology enabled knowledge exchange: development of a conceptual framework. <i>Journal of Medical Systems</i> , <b>2011</b> , 35, 713-21	5.1	2
36	Diagnostic testing for vaccinomics: is the regulatory approval framework adequate? A comparison of Canada, the United States, and Europe. <i>OMICS A Journal of Integrative Biology</i> , <b>2011</b> , 15, 597-605	3.8	2
35	Improving pediatric drug safety: need for more efficient clinical translation of pharmacovigilance knowledge. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , <b>2011</b> , 18, e76-88	3.3	11
34	Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , <b>2011</b> , 18, e106-20	3.3	6
33	Regulatory approval for new pharmacogenomic tests: a comparative overview. <i>Food and Drug Law Journal</i> , <b>2011</b> , 66, 1-24, i		5

32	Communicating pharmacogenetic research results to breastfeeding mothers taking codeine: a pilot study of perceptions and benefits. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 88, 792-5	6.1	21
31	Demonstrating utility of pharmacogenetics in pediatric populations: methodological considerations. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 88, 757-9	6.1	5
30	Direct health care costs associated with asthma in British Columbia. <i>Canadian Respiratory Journal</i> , <b>2010</b> , 17, 74-80	2.1	96
29	The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology. <i>Thyroid</i> , <b>2010</b> , 20, 681-7	6.2	49
28	Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. <i>Pediatrics</i> , <b>2010</b> , 126, e986-9	7.4	75
27	Pharmacogenomics and active surveillance for serious adverse drug reactions in children. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 1269-85	2.6	16
26	Cases: Cocaine adulterant linked to neutropenia. <i>Cmaj</i> , <b>2010</b> , 182, 57-9	3.5	23
25	Palivizumab for the prevention of respiratory syncytial virus infection. <i>Canadian Family Physician</i> , <b>2010</b> , 56, 769-72	0.9	13
24	Application of principal component analysis to pharmacogenomic studies in Canada. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 362-72	3.5	20
23	Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2009</b> , 18, 713-21	2.6	53
22	Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 85, 31-5	6.1	240
21	Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. <i>Nature Genetics</i> , <b>2009</b> , 41, 1345-9	36.3	243
20	The added burden of comorbidity in patients with asthma. <i>Journal of Asthma</i> , <b>2009</b> , 46, 1021-6	1.9	42
19	Use of oseltamivir in children. <i>Canadian Family Physician</i> , <b>2009</b> , 55, 1199-201	0.9	10
18	Identifying persons with treated asthma using administrative data via latent class modelling. <i>Health Services Research</i> , <b>2008</b> , 43, 733-54	3.4	27
17	Statin use and the risk of Parkinson disease: a nested case control study. <i>Journal of Clinical Neuroscience</i> , <b>2008</b> , 15, 1272-3	2.2	28
16	Drug formulary decision-making in two regional health authorities in British Columbia, Canada. <i>Health Policy</i> , <b>2008</b> , 88, 308-16	3.2	12
15	Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study. <i>Journal of Clinical Neuroscience</i> , <b>2008</b> , 15, 576-7	2.2	44

14	Camouflaged sampling and contacting of people from administrative databases: reaching target patients without knowing who they are. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2008</b> , 17, 790-7	2.6	1
13	Medication errors: neonates, infants and children are the most vulnerable!. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , <b>2008</b> , 13, 65-7	1.6	6
12	Genotypic approaches to therapy in children: a national active surveillance network (GATC) to study the pharmacogenomics of severe adverse drug reactions in children. <i>Annals of the New York Academy of Sciences</i> , <b>2007</b> , 1110, 177-92	6.5	22
11	Effect of a clinical pathway on the hospitalisation rates of children with asthma: a prospective study. <i>Archives of Disease in Childhood</i> , <b>2007</b> , 92, 60-6	2.2	73
10	Pharmacogenomics and its implications for autoimmune disease. <i>Journal of Autoimmunity</i> , <b>2007</b> , 28, 122-8	15.5	22
9	Paediatric adverse drug reaction reporting: understanding and future directions. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , <b>2007</b> , 14, e45-57	2	17
8	Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , <b>2005</b> , 193, 153-63	6.4	118
7	Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. <i>BMJ, The</i> , <b>2004</b> , 328, 560	5.9	53
6	The Dimensionality and Gender Differential Item Functioning of the Mini Asthma Quality of Life Questionnaire (MiniAQLQ). <i>Social Indicators Research</i> , <b>2004</b> , 68, 91-105	2.7	8
5	Quantifying adverse drug events : are systematic reviews the answer?. <i>Drug Safety</i> , <b>2004</b> , 27, 757-61	5.1	17
4	Active surveillance systems for pediatric adverse drug reactions: an idea whose time has come. <i>Current Therapeutic Research</i> , <b>2001</b> , 62, 738-742	2.4	8
3	Evidence-based pharmacotherapy: review of basic concepts and applications in clinical practice. <i>Annals of Pharmacotherapy</i> , <b>1998</b> , 32, 1193-200	2.9	11
2	Simple approach to dosage adjustment in patients with renal impairment. <i>American Journal of Health-System Pharmacy</i> , <b>1997</b> , 54, 2505-9	2.2	7
1	Comment: cost of rhDNase in cystic fibrosis. <i>Annals of Pharmacotherapy</i> , <b>1995</b> , 29, 1050-1	2.9	2